Single dose of IDA

Phase 2Small molecule

WWashington University School of Medicine

Single dose of IDA is one of 10 small molecule programs targeting Onchocerciasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OnchocerciasisActive, not recruiting

OnchocerciasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Onchocerciasis

#DrugCompanyPhaseTrials

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

7 2

Rifadin

Sanofi

Approved

—3

Cydectin

MMedicines Development for Global Health

Approved

3 4

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Albendazole.

2 6

Emodepside

JJennifer Keiser

Phase 2

1 7

Single dose of IDA

WWashington University School of Medicine

Phase 2

1 8

Hetrazan

WWyeth-Lederle Vaccines

Preclinical

1 9

Albenza

IImpax Laboratories, LLC

Preclinical

1 10

Bi-Annual CDTI

UUniversiteit Antwerpen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Onchocerciasis1 trial

Safety and Efficacy of IDA for Onchocerciasis

Completed·WWashington University School of Medicine·Phase 2·NCT04188301·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Single dose of IDA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Single dose of IDA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Single dose of IDA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWashington University School of Medicine

Single dose of IDA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Onchocerciasis1 trial

References

Drug Info

Quick Facts

Related News